Preclinical therapeutics ex ovo quail eggs as a biomimetic automation-ready xenograft platform

Samuel V. Rasmussen, Noah E. Berlow, Lisa Hudson Price, Atiya Mansoor, Stefano Cairo, Sandra Rugonyi, Charles Keller

Research output: Contribution to journalArticlepeer-review

Abstract

Preclinical cancer research ranges from in vitro studies that are inexpensive and not necessarily reflective of the tumor microenvironment to mouse studies that are better models but prohibitively expensive at scale. Chorioallantoic membrane (CAM) assays utilizing Japanese quail (Coturnix japonica) are a cost-effective screening method to precede and minimize the scope of murine studies for anti-cancer efficacy and drug toxicity. To increase the throughput of CAM assays we have built and optimized an 11-day platform for processing up to 200 quail eggs per screening to evaluate drug efficacy and drug toxicity caused by a therapeutic. We demonstrate ex ovo concordance with murine in vivo studies, even when the in vitro and in vivo studies diverge, suggesting a role for this quail shell-free CAM xenograft assay in the validation of new anti-cancer agents.

Original languageEnglish (US)
Article number23302
JournalScientific Reports
Volume11
Issue number1
DOIs
StatePublished - Dec 2021

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'Preclinical therapeutics ex ovo quail eggs as a biomimetic automation-ready xenograft platform'. Together they form a unique fingerprint.

Cite this